SSA
MDGL icon

Schonfeld Strategic Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-60,000
Closed -$237K – 2355
2023
Q1 		$237K Buy
60,000
+10,000
+20% +$2.72M ﹤0.01% 1469
2022
Q4 		$908K Sell
50,000
-45,300
-48% -$4.43M 0.01% 1202
2022
Q3 		$812K Buy
+95,300
New +$6.62M 0.01% 1422

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Schonfeld Strategic Advisors's MDGL Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 5,580 shares — an estimated $1.85M sold.

Schonfeld Strategic Advisors first reported a position in MDGL in Q1 2018 and held it in 23 quarters. The position peaked at $12.8M in Q3 2018. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 5,580 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $1.85M.
  • Schonfeld Strategic Advisors first reported a position in Madrigal Pharmaceuticals in Q1 2018 and held it in 23 quarters.
  • Schonfeld Strategic Advisors's Madrigal Pharmaceuticals position peaked at $12.8M in Q3 2018.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.